Pharmalot -- Just three months after the FDA rejected the new Brilinta bloodthinner from AstraZeneca, France is now reportedly giving the drugmaker a hard time as well. Even though the European Medicines Agency already endorsed the treatment, the HAS health technology assessment agency in France has decided the med has an unfavorable risk/benefit profile, which puts a halt to final pricing talks and a product launch, according to an investor note from Sanford Bernstein analyst Tim Anderson.
